SCHEMBL491085

SCHEMBL491085

CCCCC(CC)COC(=O)CCc1cc(OC)ccc1OC

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.53
TDP1 Q9NUW8 2/20 0.53
TSHR P16473 2/20 0.53
ATM Q13315 1/20 0.53
ALDH1A1 P00352 4/20 0.49
MAPK1 P28482 2/20 0.49
MTNR1A P48039 1/20 0.46
MTNR1B P49286 1/20 0.46
CA2 P00918 1/20 0.45
HSD17B10 Q99714 2/20 0.43
CNR1 P21554 1/20 0.42
CNR2 P34972 1/20 0.42
LMNA P02545 2/20 0.42
ADRA1A P35348 1/20 0.42
TAAR1 Q96RJ0 1/20 0.42
CAPN1 P07384 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL490567 0.91 CYP3A4 (0.53) CYP3A4TDP1TSHRATMALDH1A1
SCHEMBL490368 0.87 CYP3A4 (0.53) CYP3A4TDP1TSHRATMALDH1A1
SCHEMBL490993 0.86 CYP3A4 (0.58) CYP3A4TDP1TSHRATMALDH1A1
SCHEMBL490513 0.84 TDP1 (0.53) CYP3A4TDP1TSHRATMALDH1A1
SCHEMBL490326 0.84 CYP3A4 (0.58) CYP3A4TDP1TSHRATMALDH1A1
SCHEMBL490359 0.83 CYP3A4 (0.54) CYP3A4TDP1TSHRATMALDH1A1
SCHEMBL490514 0.82 TDP1 (0.59) CYP3A4TDP1TSHRATMALDH1A1
SCHEMBL490484 0.82 CYP3A4 (0.56) CYP3A4TDP1TSHRATMALDH1A1
SCHEMBL490725 0.81 CYP3A4 (0.61) CYP3A4TDP1TSHRATMALDH1A1
SCHEMBL14566060 0.81 TDP1 (0.57) CYP3A4TDP1TSHRATMALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8268293-B2 Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives MERCK PATENT GMBH (DE) 2012-09-18 US disclosed
US-8106233-B2 Applying di-2-ethylhexyl 4-hydroxy-3,5-dimethoxy-benzylmalonate; protective action against UV rays, oxidative stress on body cells, counters skin ageing MERCK PATENT GMBH (DE) 2012-01-31 US disclosed
US-20080171004-A1 Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives MERCK PATENT GMBH (DE) 2008-07-17 US disclosed
US-20080152603-A1 Antioxidants SUSONITY Commercial GmbH (DE) 2008-06-26 US disclosed
EP-1871339-A1 UV PROTECTION Merck Patent GmbH (DE) 2008-01-02 EP disclosed
WO-2006111234-A1 UV PROTECTION MERCK PATENT GMBH (DE) 2006-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080152603-A1 Antioxidants GPX4, GPX1, CAT CYP3A4 392/4885TDP1 1049/4885TSHR 4679/4885
US-20080171004-A1 Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives HPD, HAAO, UGT1A6 CYP3A4 63/4885TDP1 2793/4885TSHR 4810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.